BR112021025512A2 - Exossomos para tratamento de doenças - Google Patents

Exossomos para tratamento de doenças

Info

Publication number
BR112021025512A2
BR112021025512A2 BR112021025512A BR112021025512A BR112021025512A2 BR 112021025512 A2 BR112021025512 A2 BR 112021025512A2 BR 112021025512 A BR112021025512 A BR 112021025512A BR 112021025512 A BR112021025512 A BR 112021025512A BR 112021025512 A2 BR112021025512 A2 BR 112021025512A2
Authority
BR
Brazil
Prior art keywords
exosomes
disorders
population
conditions
diseases
Prior art date
Application number
BR112021025512A
Other languages
English (en)
Portuguese (pt)
Inventor
Bhavani Stout
M Hariri Haley
Navjot Shah
Qian Ye
J Hariri Robert
Shuyang He
Srinivas Somanchi
Xiaokui Zhang
Original Assignee
Celularity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celularity Inc filed Critical Celularity Inc
Publication of BR112021025512A2 publication Critical patent/BR112021025512A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48Reproductive organs
    • A61K35/50Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0603Embryonic cells ; Embryoid bodies
    • C12N5/0605Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141MicroRNAs, miRNAs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
BR112021025512A 2019-06-19 2020-06-19 Exossomos para tratamento de doenças BR112021025512A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962863767P 2019-06-19 2019-06-19
US201962891700P 2019-08-26 2019-08-26
US201962905117P 2019-09-24 2019-09-24
US201962924147P 2019-10-21 2019-10-21
PCT/US2020/038828 WO2020257720A1 (en) 2019-06-19 2020-06-19 Exosomes for disease treatment

Publications (1)

Publication Number Publication Date
BR112021025512A2 true BR112021025512A2 (pt) 2022-02-01

Family

ID=71662298

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021025512A BR112021025512A2 (pt) 2019-06-19 2020-06-19 Exossomos para tratamento de doenças

Country Status (13)

Country Link
US (1) US20230181649A1 (https=)
EP (1) EP3986381A1 (https=)
JP (1) JP2022538004A (https=)
KR (1) KR20220024060A (https=)
CN (1) CN114302731A (https=)
AU (1) AU2020298316A1 (https=)
BR (1) BR112021025512A2 (https=)
CA (1) CA3142020A1 (https=)
IL (1) IL288958A (https=)
MX (1) MX2021015528A (https=)
PH (1) PH12021553167A1 (https=)
WO (1) WO2020257720A1 (https=)
ZA (1) ZA202109828B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801028A4 (en) 2018-05-30 2022-04-13 Direct Biologics LLC A growth factor and extracellular vesicle frozen or powdered additive comprising a mesenchymal stem cell (msc) preparation and methods of use
US12569517B2 (en) 2019-02-07 2026-03-10 Direct Biologics, Llc Method for treating osteoarthritis with mesenchymal stem cell exosomes
US12213995B2 (en) 2019-07-18 2025-02-04 Direct Biologics, Llc Preparations comprising mesenchymal stem cells and cannabinoids and methods of their use
US20210322483A1 (en) 2020-04-16 2021-10-21 Ichilov Tech Ltd. Cell-derived particles presenting heterologous cd24 and use thereof in therapy
US20210324339A1 (en) 2020-04-16 2021-10-21 Ichilov Tech Ltd. Cell-derived particles presenting heterologous cd24 and use thereof in therapy
KR20230004709A (ko) 2020-04-22 2023-01-06 다이렉트 바이오로직스 엘엘씨 감염성 질환과 연관된 염증성 병태를 치료하기 위한 방법 및 조성물
KR102317052B1 (ko) * 2020-05-04 2021-10-25 주식회사 티에스셀바이오 태반 유래의 세포외 소포의 항염증 항바이러스 효과 조성물
WO2022154149A1 (ko) * 2021-01-14 2022-07-21 (주)엑솔런스 세포외소포체를 이용한 백신 조성물
WO2022183047A1 (en) * 2021-02-26 2022-09-01 The Methodist Hospital Regulatory t cell (treg) extracellular vesicle compositions and methods
CN113171379A (zh) * 2021-04-28 2021-07-27 奥启(深圳)创投科技有限公司 一种间充质干细胞外泌体在制备脂肪性肝病药物中的应用
CN114085817B (zh) * 2021-11-26 2025-04-15 三代康年(上海)医疗科技有限公司 一种包载microRNA的外泌体的制备方法及其产品和应用
CN119013038A (zh) * 2022-04-08 2024-11-22 创新外科再生控股有限公司 用于伤口愈合和促进毛发生长和/或再生的nampt
CN117414415B (zh) * 2023-07-10 2024-10-18 中山大学·深圳 蛋白质精氨酸甲基转移酶7在促进毛发生长中的应用
WO2025048567A1 (ko) * 2023-08-31 2025-03-06 의료법인 성광의료재단 인간 태반 유래 중간엽 줄기 세포에서 분리된 엑소좀을 포함하는 시신경 질환 및 미토콘드리아 기능이상 질환 예방 또는 치료용 약학적 조성물
KR20250139693A (ko) * 2024-03-15 2025-09-23 가톨릭대학교 산학협력단 Ssea3 및 cd105를 발현하는 신경능 유래 코 줄기세포 유효성분으로 포함하는 알츠하이머병 예방 또는 치료용 약학적 조성물
US12502407B2 (en) 2024-04-25 2025-12-23 Direct Biologics, Llc Treatment of fistula with bone marrow mesenchymal stem cell derived extracellular vesicles
CN120437174A (zh) * 2025-02-28 2025-08-08 单核细胞治疗有限公司 脐带血外泌体在制备治疗衰老引发的眼科疾病的药物中的应用
CN120927522B (zh) * 2025-10-14 2026-02-03 亿航(苏州)生物医药有限公司 辅助诊断或鉴别血管性认知障碍的标志物、试剂盒及用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1969147B1 (en) * 2006-01-05 2014-07-30 The Ohio State University Research Foundation microRNA-based methods for the diagnosis of stomach cancer
EP3115469B1 (en) * 2007-11-19 2020-04-29 Celera Corporation Lung cancer markers and uses thereof
CN102307475A (zh) * 2009-02-04 2012-01-04 彼帕科学公司 用与生长因子抑制剂组合的parp抑制剂治疗肺癌
WO2016057755A1 (en) * 2014-10-09 2016-04-14 Anthrogenesis Corporation Placenta-derived adherent cell exosomes and uses thereof
MX2017015147A (es) * 2015-05-26 2018-03-28 Celularity Inc Angiogenesis usando celulas madre de placenta estimuladas.
CN105861430B (zh) * 2016-04-29 2019-07-23 南京大学 一种外泌体、外泌体的制备方法及其在制备治疗脓毒症药物或者制剂中的应用
KR20190109389A (ko) * 2016-11-03 2019-09-25 엑소스템 바이오텍 리미티드 간엽 줄기 세포 집단, 이들의 산물 및 이들의 용도
MX2020005100A (es) * 2017-11-16 2020-11-24 Celularity Inc Cultivo de placenta para aislar exosomas.

Also Published As

Publication number Publication date
ZA202109828B (en) 2024-04-24
KR20220024060A (ko) 2022-03-03
WO2020257720A1 (en) 2020-12-24
CN114302731A (zh) 2022-04-08
US20230181649A1 (en) 2023-06-15
EP3986381A1 (en) 2022-04-27
MX2021015528A (es) 2022-02-03
JP2022538004A (ja) 2022-08-31
IL288958A (en) 2022-02-01
AU2020298316A1 (en) 2021-12-16
CA3142020A1 (en) 2020-12-24
PH12021553167A1 (en) 2022-08-15

Similar Documents

Publication Publication Date Title
BR112021025512A2 (pt) Exossomos para tratamento de doenças
ZA202502749B (en) Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders
ZA202001057B (en) Inhibiting ubiquitin specific peptidase 30
EP4653048A3 (en) Therapeutic use of mitochondria and combined mitochondrial agents
JOP20190147A1 (ar) تركيبات حمض أميني وطرق لمعالجة أمراض واضطرابات العضلات
MX2017003966A (es) Composiciones de tratamiento y/o limpieza que comprenden composiciones para reducir el mal olor.
MX2018005019A (es) Derivado benzofurano, su metodo de preparacion, y sus usos en medicinas.
MX2025010483A (es) Uso de anticuerpos y composiciones que los comprenden para tratar enfermedades y trastornos mediados por complemento
WO2015101958A3 (en) Inhibitors of glutaminase
MX2017003624A (es) Compuestos de piridona sustituida con pirazolilo como inhibidores de serina proteasas.
MY201921A (en) Agent for preventing or treating fat-associated diseases and/or inflammation
MX2017015012A (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
MY207469A (en) Therapeutic compounds
MY185412A (en) Compositions of omega 3 fatty acids to treat diseases which involve damage to the nervous system
MX2019004859A (es) Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
ZA202002779B (en) Dantrolene prodrugs and methods of their use
WO2015142500A3 (en) Compositions and methods for treating addiction
EP4275761A3 (en) Alkaline phosphatase agents for treatment of radiation disorders
PH12020551071A1 (en) Compositions and methods for treating retinal disorders
CL2017000475A1 (es) Composición para formulación cosmética que consiste en una mezcla de hasta 3 componentes seleccionados de manteca de murumuru, manteca de ucuuba, aceite de nuez de brasil, aceite de maracuyá, manteca de copoazú, aceite de acai y aceite de andiroba y/o ésteres de los mismos; producto cosmético.
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
EA201590884A1 (ru) Способы лечения заболеваний печени
EA202191115A1 (ru) Новые пиридазины
MX2021008188A (es) Compuestos de anandamida.
EP3973030A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT AND RELIEF OF ALCOHOLIC-INDUCED SKIN REMOVAL

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2832 DE 15-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.